Drug Approval | July 24, 2024
Zydus receives USFDA’s final approval for Valsartan Tablets
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India
Reported profit after tax declined 19% year-on-year to Rs 76 crores
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23
This transaction is the third acquisition by three different Japanese players in this segment
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
The facility is a part of Lupin Manufacturing Solutions
Subscribe To Our Newsletter & Stay Updated
